Nanjing Biotech and Pharmaceutical Valley Construction and Development

Nanjing Biotech and Pharmaceutical Valley Construction and Development

Nanjing Biotech and Pharmaceutical Valley Construction and Development was established in 2011 as the primary development vehicle for the Nanjing Biotech and Pharmaceutical Valley, a state-designated industrial park within the Jiangbei New Area. The entity is a nearly wholly-owned subsidiary of Nanjing Jiangbei New Area Industry Investment Group, which holds a 91.61% equity stake and anchors the firm inside the municipal government's economic development apparatus. The firm's physical footprint includes the Life Science Island complex, multiple phases of R&D buildings operated under the China-Denmark Park banner, and the National Science and Technology Enterprise Incubators — a portfolio of commercial and industrial real estate designed to attract and house biotech tenants. The firm deploys capital across several mechanisms. It develops and leases specialized laboratory and manufacturing facilities to biotech tenants, operates state-backed incubator programs, and participates as a limited partner in a 1.78 billion yuan industrial fund alongside strategic partners New Hope Group, CITIC Agriculture, and SUMEC. The investment mandate spans gene therapy, CAR-T cell therapy, pharmaceutical R&D, medical equipment, and biopharmaceuticals — essentially the full stack of China's targeted biotech modernization push. The Jiangbei New Area itself positions the biotech valley as a key node in China's national strategy to build domestic pharmaceutical innovation capacity, and this firm is the on-the-ground entity that constructs and fills that infrastructure. In 2016, Nanjing Yangzi State-owned Investment Group participated in an A-round financing for the company, reinforcing the municipal-level commitment to the biotech cluster strategy. The firm also manages several specialized assets: the Talent Building, designed to house skilled returnees and researchers under government talent schemes; the Nanjing Overseas Students Pioneer Park, which specifically targets Chinese scientists returning from abroad; and the China-Denmark R&D collaboration buildings, suggesting an ongoing effort to anchor international research partnerships within the park. Zhou Qiang appears as the current Legal Representative, though the professional management team and staffing levels are not publicly available. The firm's core structural distinction lies in its hybrid mandate: it is simultaneously a real-estate developer building specialized biotech infrastructure, a corporate venture-style investor allocating capital into resident companies via government-sponsored funds, and a state economic-development tool embedded in Nanjing's municipal government. That triple identity — landlord, investor, and policy instrument — separates it from independent venture firms while aligning it closely with other Chinese state-backed park developers like Suzhou BioBay and Wuhan Biolake. Its governance flows upward to the Jiangbei New Area government, making its investment decisions inherently tied to municipal industrial-policy priorities rather than standalone fiduciary returns.